那他珠单抗疗效减退效应:周期末多发性硬化症状复发
结果显示54%的患者报告曾出现疗效减退效应,32%在测量时正经历该效应,且该效应与那他珠单抗浓度及α4-整合素受体饱和度均无关,标准间隔组报告率高于延长间隔组。
要点
- 54%的患者报告曾出现那他珠单抗疗效减退效应,32%在测量时正经历该效应
- 疗效减退效应与那他珠单抗浓度及α4-整合素受体饱和度均无关
- 标准间隔组报告率(39%)高于延长间隔组(19%),症状持续时间两组相当
核心结论
- 疗效减退效应是患者频繁报告的现象,但不太可能反映药代动力学/药效学状态不理想。
- 未发现能预测疗效减退效应的危险因素。
研究设计与样本
- 纳入标准为至少接受6次那他珠单抗输注,要求完成多发性硬化影响量表、36项简表健康调查及关于疗效减退效应的通用问卷。
- 在再次给药前测量那他珠单抗浓度和α4-整合素受体饱和度。
主要发现
- 54%的患者在治疗期间经历疗效减退效应,32%在测量时正经历当前疗效减退效应。
- 自我报告的疗效减退效应与那他珠单抗浓度及α4-整合素受体饱和度均无关。
- 标准间隔组报告疗效减退效应的比例为39%,延长间隔组为19%,两组症状持续时间相当。
- 疗效减退效应与输注次数、病程、年龄或性别均无关。
临床怎么用
- 临床中患者报告周期末症状加重时,不应仅归因于血药浓度不足或受体饱和度下降。
- 标准间隔给药患者报告疗效减退效应更频繁,但症状持续时间与延长间隔组相当,决策时需综合评估。
局限性
- 疗效减退效应基于患者自我报告问卷,缺乏客观临床评估。
- 未发现预测因素,可能受样本量及研究设计限制。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Natalizumab is effective in treating relapsing-remitting multiple sclerosis (RRMS). However, many patients report an increase of multiple sclerosis symptoms at the end of the natalizumab cycle: a wearing-off effect. The objective of this study was to evaluate the prevalence of the wearing-off effect in patients with standard and extended intervals and to study possible associations with pharmacokinetic/dynamic measurements and patient characteristics in a prospective, monocenter, cross-sectional cohort study. METHODS: Patients with RRMS, with a minimum of 6 natalizumab infusions, were asked to complete 3 questionnaires: the Multiple Sclerosis Impact Scale, the 36-Item Short Form Health Survey, and a general questionnaire regarding the wearing-off effect. Natalizumab concentration and α4-integrin receptor saturation were measured before redosing. RESULTS: Ninety-three patients were included. A total of 54% experienced a wearing-off effect during natalizumab treatment and 32% experienced a current wearing-off effect at time of measurement. The self-reported wearing-off effect was not associated with natalizumab concentration nor with α4-integrin receptor saturation. The wearing-off effect was more frequently reported in the standard interval group (39%) than in the extended interval group (19%); the duration of symptoms was comparable between both groups. The wearing-off effect was not associated with number of infusions, disease duration, age, or sex. CONCLUSION: The wearing-off effect is a frequently reported phenomenon but is unlikely to reflect a nonoptimal pharmacokinetic/dynamic state. We did not find risk factors predicting the wearing-off effect.
引用
- van Kempen ZLE, Doesburg D, Dekker I, et al. The natalizumab wearing-off effect: End of natalizumab cycle, recurrence of MS symptoms. Neurology. 2019. PMID: 31551258. doi:10.1212/WNL.0000000000008357
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。